一分钟看懂
这是一项关于卵巢癌的I 期 / II 期研究，登记的药物或干预包括SHR-A1811；Carboplatin；Bevacizumab；Oxaliplatin for Injection；Paclitaxel injection；Doxorubicin hydrochloride liposome injection；Adebrelimab In，当前状态为招募中。登记地点显示中国武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SHR-A1811；Carboplatin；Bevacizumab；Oxaliplatin for Injection；Paclitaxel injection；Doxorubicin hydrochloride liposome injection；Adebrelimab Injection · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology · 武汉
公开的入选条件
- 1. Voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with the follow-up.
- 2. Sufficient fresh or archived tumor tissue specimens can be provided for testing by the third-party central laboratory designated by the sponsor.
- 3. At least one measurable lesion conforming to RECIST v1.1.
- 4. ECOG PS score: 0-1.
- 5. Expected survival ≥ 12 weeks.
- 6. Female subjects with fertility must agree to comply with the contraceptive requirements from signing the informed consent form to 7 months after the last administration of the trial drug.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06840002；登记信息更新于 2026-09-11。